Abstract 2981
Background
PI3K/AKT/mTOR and MEK/ERK signalling pathways act cooperatively to develop taxane resistance in metastatic castration resistant prostate cancer (mCRPC). Inhibition of one of the pathways promotes a negative feedback that activates the other one. Co-inhibition of both pathways increases anti-tumor efficacy in preclinical models of PC. Our aim was to demonstrate whether combinations of Selumetinib (SELU; MEK inhibitor) + Capivasertib (CAPI; AKT inhibitor) or AZD8186 (PI3Kβ/δ inhibitor) could potentiate the effect of Cabazitaxel (CABA) treatment and revert resistance to Docetaxel (DOCE) in in vitro models.
Methods
The effect of drug treatments on the proliferation of DOCE-acquired resistant cells DU145-DR (PTEN WT/K-RAS MUT) and PC3-DR (PTEN Null/K-RAS WT) was determined by MTT assay and the median effect lines method; synergism was calculated using CompuSyn software. Phosphorylation status of AKT, ERK, GSK3β, S6 and p90RSK was analysed by Western Blot at basal level and after treatments.
Results
As compared to parental cells, p-AKT was significantly increased in DU145-DR and PC3-DR cells while p-ERK was increased in DU145-DR and decreased in PC3-DR. AZD8186 and CAPI alone showed little effect on DU145-DR cell viability (IC50>50µM). In contrast, both drugs decreased PC3-DR cell viability with IC50s of 0.5 and 1.5µM, respectively. SELU had no effect on proliferation of any cell line. SELU + CAPI and SELU + AZD8186 72h-concomitant treatment decreased DU145-DR proliferation in a highly synergistic manner, particularly the SELU + AZD8186 combination. Accordingly, this treatment was the more efficient in decreasing p-AKT and p-ERK. However, the addition of SELU didn’t enhance the efficacy of CAPI or AZD8186 in PC3-DR cells. SELU + AZD8186 promoted a dramatic increase of CABA and DOCE cytotoxicity in DU145-DR cells.
Conclusions
These results suggest that the combination of SELU + AZD8186 is highly synergistic at least in DU145-DR cells, leading to a very strong CABA sensitization and DOCE resistance reversion through the inhibition of AKT and ERK activation. Further experiments are ongoing in order to elucidate the role of these drugs in taxane sensitivity of PC3-DR and CABA-acquired resistant cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract